Related Experiment Video

Updated: May 12, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Thalidomide attenuates excessive inflammation without interrupting lipopolysaccharide-driven inflammatory cytokine

Toshinao Kawai1, Nobuyuki Watanabe, Midori Yokoyama

  • 1Department of Human Genetics, National Center for Child Health and Development, Tokyo, Japan. kawai-t@ncchd.go.jp

Clinical Immunology (Orlando, Fla.)
|April 16, 2013
PubMed

Insights

Thalidomide effectively reduced bowel inflammation in Chronic Granulomatous Disease (CGD) patients by suppressing key inflammatory signals. This treatment shows promise for CGD colitis without worsening dangerous infections.

Area of Science:

  • Immunology
  • Gastroenterology
  • Pharmacology

Background:

  • Chronic Granulomatous Disease (CGD) causes recurrent infections due to impaired reactive oxygen species production.
  • CGD patients frequently develop aseptic bowel inflammation (CGD colitis) driven by dysregulated TNF-α and IL-1β.
  • Therapies are needed to control inflammation without compromising essential antimicrobial immunity in CGD colitis.

Observation:

  • Thalidomide inhibited TNF-α-induced NF-κB activation and IL-1β secretion in CGD monocytes.
  • Crucially, thalidomide did not impair lipopolysaccharide-induced production of IL-1β, IL-6, IL-8, and TNF-α in CGD monocytes.
  • A CGD colitis patient experienced reduced bowel inflammation and inflammatory cytokines with thalidomide therapy.

Findings:

  • Thalidomide selectively modulated inflammatory pathways (NF-κB, IL-1β secretion) in CGD monocytes.
  • The drug did not abolish the innate immune response to bacterial components (lipopolysaccharide).
  • Clinical observation supported thalidomide's efficacy in reducing CGD colitis symptoms.

Implications:

  • Thalidomide represents a potential therapeutic strategy for managing CGD colitis.
  • This approach may allow for targeted anti-inflammatory effects while preserving crucial host defense mechanisms.
  • Further investigation into thalidomide for CGD colitis is warranted given its dual action on inflammation and infection control.

More Related Videos

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...